Characteristic | TK/VEGF inhibitor (n = 1752) | mTOR inhibitor (n = 233) | Oral (n = 1674) | IV (n = 318) | ||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |
Age at diagnosis, median (Q1–Q3), years | 62 (56–70) | 62 (56–71) | 61 (56–69) | 64 (57–76) | ||||
Male | 1220 | 69.6 | 166 | 71.2 | 1176 | 70.3 | 215 | 67.6 |
Employment status | ||||||||
 Active | 568 | 32.4 | 69 | 29.6 | 563 | 33.6 | 79 | 24.8 |
 Retiree | 652 | 37.2 | 78 | 33.5 | 617 | 36.9 | 113 | 35.5 |
 Long-term disability | 11 | 0.6 | 1 | 0.4 | 8 | 0.5 | 4 | 1.3 |
 Other/unknown | 521 | 29.7 | 85 | 36.5 | 486 | 29.0 | 122 | 38.4 |
Region | ||||||||
 Northeast | 327 | 18.7 | 33 | 14.2 | 303 | 18.1 | 57 | 17.9 |
 North Central | 467 | 26.7 | 52 | 22.3 | 451 | 26.9 | 68 | 21.4 |
 South | 645 | 36.8 | 104 | 44.6 | 622 | 37.2 | 131 | 41.2 |
 West | 296 | 16.9 | 40 | 17.2 | 280 | 16.7 | 59 | 18.6 |
 Unknown | 17 | 1.0 | 4 | 1.7 | 18 | 1.1 | 3 | 0.9 |
Metropolitan statistical area | ||||||||
 Urban | 1424 | 81.3 | 195 | 83.7 | 1359 | 81.2 | 267 | 84.0 |
 Rural | 328 | 18.7 | 38 | 16.3 | 315 | 18.8 | 51 | 16.0 |
Insurance plan type | ||||||||
 Comprehensive | 313 | 17.9 | 45 | 19.3 | 288 | 17.2 | 70 | 22.0 |
 HMO | 204 | 11.6 | 22 | 9.4 | 189 | 11.3 | 38 | 12.0 |
 POS | 130 | 7.4 | 17 | 7.3 | 120 | 7.2 | 28 | 8.8 |
 PPO | 926 | 52.9 | 125 | 53.7 | 896 | 53.5 | 158 | 49.7 |
 Other | 179 | 10.2 | 24 | 10.3 | 181 | 10.8 | 24 | 7.6 |
Insurance type | ||||||||
 Commercial | 1120 | 63.9 | 142 | 70.0 | 1100 | 65.7 | 169 | 53.1 |
 Medicare | 632 | 36.1 | 91 | 39.1 | 574 | 34.3 | 149 | 46.9 |
Index year | ||||||||
 2011 | 350 | 20.0 | 78 | 33.5 | 341 | 20.4 | 88 | 27. 7 |
 2012 | 350 | 20.0 | 62 | 26.6 | 333 | 19.9 | 80 | 25.2 |
 2013 | 392 | 22.4 | 25 | 10.7 | 373 | 22.3 | 45 | 14.2 |
 2014 | 327 | 18.7 | 38 | 16.3 | 309 | 18.5 | 58 | 18.2 |
 2015 | 333 | 19.0 | 30 | 12.9 | 318 | 19.0 | 47 | 14.8 |
Mean DCCI score (Q1–Q3) | 0.70 (0–1) | 0.76 (0–1) | 0.66 (0–1) | 0.93 (0–1) | ||||
Comorbidities | ||||||||
 Diabetes | 484 | 27.6 | 48 | 20.6 | 442 | 26.4 | 90 | 28.3 |
 CKD | 346 | 19.8 | 54 | 23.2 | 317 | 18.9 | 84 | 26.4 |
 Liver disease | 307 | 17.5 | 40 | 17.2 | 306 | 18.3 | 45 | 14.2 |
 COPD | 217 | 12.4 | 33 | 14.2 | 212 | 12.7 | 39 | 12.3 |
 CHF | 113 | 6.5 | 37 | 15.9 | 111 | 6.6 | 40 | 12.6 |
Secondary metastatic sites | ||||||||
 Lung | 798 | 45.6 | 101 | 43.4 | 804 | 48.0 | 99 | 31.1 |
 Liver | 181 | 10.3 | 39 | 16.7 | 186 | 11.1 | 34 | 10.7 |
 Brain | 161 | 9.2 | 25 | 10.7 | 162 | 9.7 | 26 | 8.2 |
 Bone | 469 | 26.8 | 85 | 36.5 | 479 | 28.6 | 76 | 23.9 |
 Others | 696 | 39.7 | 100 | 42.9 | 704 | 42.1 | 97 | 30.5 |
Nephrectomy prior to treatment | ||||||||
 Any nephrectomy | 395 | 22.6 | 47 | 20.2 | 390 | 23.3 | 53 | 16.7 |
 Cytoreductive nephrectomy | 380 | 21.7 | 41 | 17.6 | 377 | 22.5 | 45 | 14.2 |